455 related articles for article (PubMed ID: 31028088)
1. High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden.
Benayed R; Offin M; Mullaney K; Sukhadia P; Rios K; Desmeules P; Ptashkin R; Won H; Chang J; Halpenny D; Schram AM; Rudin CM; Hyman DM; Arcila ME; Berger MF; Zehir A; Kris MG; Drilon A; Ladanyi M
Clin Cancer Res; 2019 Aug; 25(15):4712-4722. PubMed ID: 31028088
[TBL] [Abstract][Full Text] [Related]
2. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
[TBL] [Abstract][Full Text] [Related]
3. Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study.
Velizheva NP; Rechsteiner MP; Valtcheva N; Freiberger SN; Wong CE; Vrugt B; Zhong Q; Wagner U; Moch H; Hillinger S; Schmitt-Opitz I; Soltermann A; Wild PJ; Tischler V
Pathol Res Pract; 2018 Apr; 214(4):572-578. PubMed ID: 29580750
[TBL] [Abstract][Full Text] [Related]
4. Detection of multiple types of cancer driver mutations using targeted RNA sequencing in non-small cell lung cancer.
Ju S; Cui Z; Hong Y; Wang X; Mu W; Xie Z; Zeng X; Su L; Lin X; Zhang Z; Zhang Q; Song X; You S; Chen R; Chen W; Xu C; Zhao J
Cancer; 2023 Aug; 129(15):2422-2430. PubMed ID: 37096747
[TBL] [Abstract][Full Text] [Related]
5. Common driver mutations and smoking history affect tumor mutation burden in lung adenocarcinoma.
Nagahashi M; Sato S; Yuza K; Shimada Y; Ichikawa H; Watanabe S; Takada K; Okamoto T; Okuda S; Lyle S; Takabe K; Tsuchida M; Wakai T
J Surg Res; 2018 Oct; 230():181-185. PubMed ID: 30072189
[TBL] [Abstract][Full Text] [Related]
6. Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer.
Claerhout S; Lehnert S; Vander Borght S; Spans L; Dooms C; Wauters E; Vansteenkiste J; Weynand B; Deraedt K; Bourgain C; Vanden Bempt I
Lung Cancer; 2022 Apr; 166():242-249. PubMed ID: 35378489
[TBL] [Abstract][Full Text] [Related]
7. Histological characteristics of lung adenocarcinoma with uncommon actionable alterations: special emphasis on MET exon 14 skipping alterations.
Hayashi T; Kohsaka S; Takamochi K; Kishikawa S; Ikarashi D; Sano K; Hara K; Onagi H; Suehara Y; Takahashi F; Saito T; Nakatsura T; Kitano S; Suzuki K; Yao T
Histopathology; 2021 Jun; 78(7):987-999. PubMed ID: 33249657
[TBL] [Abstract][Full Text] [Related]
8. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes.
Chang JC; Offin M; Falcon C; Brown D; Houck-Loomis BR; Meng F; Rudneva VA; Won HH; Amir S; Montecalvo J; Desmeules P; Kadota K; Adusumilli PS; Rusch VW; Teed S; Sabari JK; Benayed R; Nafa K; Borsu L; Li BT; Schram AM; Arcila ME; Travis WD; Ladanyi M; Drilon A; Rekhtman N
Clin Cancer Res; 2021 Jul; 27(14):4066-4076. PubMed ID: 33947695
[TBL] [Abstract][Full Text] [Related]
10. The landscape and therapeutic relevance of cancer-associated transcript fusions.
Yoshihara K; Wang Q; Torres-Garcia W; Zheng S; Vegesna R; Kim H; Verhaak RG
Oncogene; 2015 Sep; 34(37):4845-54. PubMed ID: 25500544
[TBL] [Abstract][Full Text] [Related]
11. Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas.
Li Y; Gao L; Ma D; Qiu T; Li W; Li W; Guo L; Xing P; Liu B; Deng L; Fu J; Li J; Yu Y; Ying J
Lung Cancer; 2018 Aug; 122():113-119. PubMed ID: 30032818
[TBL] [Abstract][Full Text] [Related]
12. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
[TBL] [Abstract][Full Text] [Related]
13. Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with
Offin M; Rizvi H; Tenet M; Ni A; Sanchez-Vega F; Li BT; Drilon A; Kris MG; Rudin CM; Schultz N; Arcila ME; Ladanyi M; Riely GJ; Yu H; Hellmann MD
Clin Cancer Res; 2019 Feb; 25(3):1063-1069. PubMed ID: 30045933
[TBL] [Abstract][Full Text] [Related]
14. Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients.
Ross DS; Liu B; Schram AM; Razavi P; Lagana SM; Zhang Y; Scaltriti M; Bromberg JF; Ladanyi M; Hyman DM; Drilon A; Zehir A; Benayed R; Chandarlapaty S; Hechtman JF
Ann Oncol; 2020 Aug; 31(8):991-1000. PubMed ID: 32348852
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods.
Kao HL; Yeh YC; Lin CH; Hsu WF; Hsieh WY; Ho HL; Chou TY
Lung Cancer; 2016 Nov; 101():40-47. PubMed ID: 27794407
[TBL] [Abstract][Full Text] [Related]
16. Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor.
Yeung SF; Tong JHM; Law PPW; Chung LY; Lung RWM; Tong CYK; Chow C; Chan AWH; Wan IYP; Mok TSK; To KF
J Thorac Oncol; 2015 Sep; 10(9):1292-1300. PubMed ID: 26098749
[TBL] [Abstract][Full Text] [Related]
17. Profiling Receptor Tyrosine Kinase Fusions in Chinese Breast Cancers.
Tao Z; Liu J; Li T; Xu H; Chen K; Zhang J; Zhou H; Sun J; Han J; Guo Z; Yang H; Cao WM; Hu X
Front Oncol; 2021; 11():741142. PubMed ID: 34650924
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA.
Supplee JG; Milan MSD; Lim LP; Potts KT; Sholl LM; Oxnard GR; Paweletz CP
Lung Cancer; 2019 Aug; 134():96-99. PubMed ID: 31320002
[TBL] [Abstract][Full Text] [Related]
19. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
[TBL] [Abstract][Full Text] [Related]
20. Identification of Novel CD74-NRG2α Fusion From Comprehensive Profiling of Lung Adenocarcinoma in Japanese Never or Light Smokers.
Kohsaka S; Hayashi T; Nagano M; Ueno T; Kojima S; Kawazu M; Shiraishi Y; Kishikawa S; Suehara Y; Takahashi F; Takahashi K; Suzuki K; Takamochi K; Mano H
J Thorac Oncol; 2020 Jun; 15(6):948-961. PubMed ID: 32036070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
